Next-generation CDK inhibitors in HR+/HER2– breast cancer
Open Access
- 15 October 2026
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (20)
Abstract
Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 – ) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy has transformed treatment paradigms and established cell-cycle targeting as a cornerstone of care. However, important challenges remain, including hematologic toxicity, incomplete and largely cytostatic responses, and the near-universal development of resistance. These limitations have highlighted the need for next-generation CDK-directed strategies capable of improving selectivity, extending disease control, and overcoming adaptive escape pathways. This Review examines the evolving landscape of CDK-targeted therapeutics in breast cancer, with particular emphasis on emerging CDK4-selective inhibitors, CDK2-directed approaches, and broader multi-CDK strategies. We discuss the biological rationale underpinning these agents, the mechanisms of resistance that have informed their development, and the clinical opportunities they may create across both advanced and early-stage settings. By refining target specificity and addressing resistance-associated cell-cycle rewiring, next-generation CDK inhibitors may reduce toxicity, enhance treatment durability, and enable more effective combination and sequencing strategies. Collectively, these advances promise to move breast cancer treatment beyond current CDK4/6 inhibition toward more precise, adaptable, and durable cell-cycle–directed therapy.Keywords
This publication has 104 references indexed in Scilit:
- 974P First-in-human phase I dose finding study of INCB123667, a selective CDK2 inhibitor, in patients with advanced solid tumorsAnnals of Oncology, 2025
- 520P Long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+/HER2− metastatic breast cancer (mBC)Annals of Oncology, 2025
- 413P Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitorsAnnals of Oncology, 2024
- 618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumorsAnnals of Oncology, 2024
- Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast CancerJAMA Oncology, 2023
- Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2022
- The role of CDK6 in cancerInternational Journal of Cancer, 2020
- Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulationBiochemical Pharmacology, 2019
- Selective degradation of CDK6 by a palbociclib based PROTACBioorganic & Medicinal Chemistry Letters, 2019
- Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6Angewandte Chemie International Edition, 2019